Cardium Therapeutics has developed a unique portfolio of businesses and product opportunities in the fields of health sciences and regenerative medicine. Among other opportunities in its portfolio, the company’s lead clinical development product candidate, Generx®, is being developed to treat patients with advanced coronary artery disease (CAD). The market for this disease is tremendous – in 2012, CAD was the most common cause of death in the world, according to the World Health Organization.

While healthy lifestyle changes greatly reduce the risk and prominence of CAD, it remains a significant medical challenge worldwide and is especially an issue in markets where persons with the disease may not have access to healthy lifestyle education or adequate healthcare.

Cardium’s focus is on providing Generx to individuals in international markets outside the United States. The therapeutic candidate is designed as an alternative for patients who may not be candidates for or who don’t have access to the costly and invasive surgical procedures such as coronary artery bypass surgery and angioplasty/stents. In the U.S., these procedures can cost a staggering $50,000-$100,000 over a five-year period following the initial treatment.

Generx is a regenerative medicine therapy that stimulates structural and physiological changes in the heart by promoting the growth of new collateral blood vessels following a significantly less invasive, one-time injection into the heart via standard cardiac infusion catheter. The candidate’s capability to elicit blood vessel growth greatly contrasts traditional drug therapies that provide relief for anginal chest pain without changing the underlying disease.

Cardium is conducting ASPIRE Phase 3 registration at leading cardiology centers in the Russian Federation to evaluate the therapeutic effects of Generx in patients with myocardial ischemia due to coronary artery disease.

For more information visit www.cardiumthx.com

Let us hear your thoughts below: